Hemophilia A
Conditions
Keywords
Bleeding disorder, Coagulation factor VIII, Blood Coagulation Disorders
Brief summary
People with hemophilia A do not have enough of a protein found naturally in the blood called clotting factor 8, also known as FVIII. This protein helps the blood to clump together to prevent and stop bleeding. People with lower levels of FVIII or FVIII that does not work properly may bleed for a long time from minor wounds, bleed into their joints, or have internal bleeding. The study treatment, Jivi (also called damoctocog alfa pegol), is already available as a treatment for people aged 12 years and older with hemophilia A, to help prevent bleeding, also known as prophylactic treatment. It works by replacing the missing FVIII, or the FVIII that does not work properly. It can also be used to stop bleeding that has already occurred and prior to surgery to prevent bleeding. The main goal of this study is to learn how damoctocog alfa pegol is used in the real world as a treatment in the United States (US) and how well it works and what other treatments patients use while receiving damoctocog alfa pegol treatment. It will also determine how satisfied people are with the treatment. There will be no required visits with a study doctor in this study. The study will include about 20 male or female patients in the US aged 12 years and over who have hemophilia A. All the patients in this study will have switched from their previous FVIII replacement treatment to damoctocog alfa pegol. While the patients are receiving damoctocog alfa pegol, they will complete a survey to say how they feel about the treatment. Their doctors will also record information about their treatment with damoctocog alfa pegol and how well it is working. This study will collect information from the patients' medical records and surveys. They will use this information to find out more about treatment with damoctocog alfa pegol under real world conditions. They will look at: * how often the patients receive damoctocog alfa pegol and how much they use * what other treatments the patients received before receiving damoctocog alfa pegol, how they used it and how much they used * how well damoctocog alfa pegol works at preventing bleeding, and how it compares to previous products used.
Interventions
OTHERNo intervention
Retrospective analysis using database without any intervention assigned in the study.
Sponsors
Bayer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female with a diagnosis of hemophilia A * Previously or currently treated with damoctocog alfa pegol for at least 6 months. * Treated with damoctocog alfa pegol per the US approved label to include: * Aged ≥12 years at the time of damoctocog alfa pegol treatment initiation * Previously treated for hemophilia A with an FVIII replacement therapy other than damoctocog alfa pegol * Treatment modality of on-demand, prophylactic, intermittent prophylaxis or a combination thereof * Have data in the medical record at the participating site as follows: * For a minimum of 6 months prior to the damoctocog alfa pegol initiation date * For a minimum of 6 months post-damoctocog alfa pegol initiation date AND the patient was receiving treatment with damoctocog alfa pegol during this 6-month follow-up period AND this data is dated prior to the central institutional review board (IRB) approval date for the study * To include the FVIII replacement therapy most recently received prior to the initiation of damoctocog alfa pegol * For patients in the prospective cohort * Signed informed consent * Current treatment with damoctocog alfa pegol or discontinued use of damoctocog alfa pegol within 3 months prior to the date of enrollment into the retrospective cohort.
Exclusion criteria
* Diagnosis of any other bleeding/coagulation disorder other than hemophilia A. * Participation in any past or current damoctocog alfa pegol interventional trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of damoctocog alfa pegol infusions | From index date through the date of central IRB approval (3 years and 8 months) | Reported as infusions. IRB: institutional review board |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Descriptive summary of damoctocog alfa pegol treatment regimen. | Up to 5 years from index date | — |
| Descriptive summary of post-damoctocog alfa pegol treatment regimen, if applicable. | Up to 4 years | Only applicable for patients who discontinue damoctocog alfa pegol treatment regime. |
| Descriptive summary of changes in pre-damoctocog alfa pegol treatment regimes | 6 months prior to the index date. | — |
| Descriptive summary of pre-damoctocog alfa pegol treatment regimen | 6 months prior to the index date. | — |
| Annualized number of spontaneous, joint, and trauma bleeds before initiation of treatment with damoctocog alfa pegol. | 6 months prior to the index date. | — |
| Annualized number of spontaneous, joint, and trauma bleeds post initiation of treatment with damoctocog alfa pegol. | Up to 5 years from index date | — |
| Descriptive summary for reasons for treatment discontinuation of pre-damoctocog alfa pegol treatment regimes. | 6 months prior to the index date. | — |
Countries
United States
Outcome results
None listed